Acadia Healthcare Company, Inc. ACHC today announced financial results for the fourth quarter and year ended December 31, 2013. For the fourth quarter, revenue was $190.0 million, a 66.3% increase from $114.3 million for the fourth quarter of 2012. Income from continuing operations was $12.4 million, or $0.25 per diluted share, for the fourth quarter of 2013 compared with $4.5 million, or $0.10 per diluted share, for the fourth quarter of 2012. Adjusted income from continuing operations was $14.5 million for the fourth quarter of 2013, up 79.0% from $8.1 million for the fourth quarter of 2012, and adjusted income from continuing operations per share increased 52.6% to $0.29 from $0.19 for the comparable quarters. Per share results reflect a 15.4% increase in weighted average shares outstanding for the fourth quarter of 2013 from the same quarter in 2012, primarily due to Acadia's public equity offering in December 2012. The adjusted results exclude transaction-related expenses of $3.3 million and $6.0 million for the fourth quarter of 2013 and 2012, respectively. A reconciliation of all GAAP and non-GAAP financial results in this release is on pages 8 and 9.
For the full year ended December 31, 2013, revenue increased 75.1% to $713.4 million from $407.5 million for 2012. Income from continuing operations for 2013 was $43.3 million, or $0.86 per diluted share, compared with $20.5 million, or $0.53 per diluted share, for 2012. Adjusted income from continuing operations increased 109.4% for 2013 to $53.6 million from $25.6 million for 2012 and increased 62.1% to $1.07 per diluted share from $0.66 per diluted share. Per share results reflect a 29.9% increase in weighted average shares outstanding for the comparable periods, primarily due to Acadia's public equity offerings in 2012. The adjusted results for 2013 exclude debt extinguishment costs of $9.4 million and transaction-related expenses of $7.2 million and, for 2012, exclude transaction-related expenses of $8.1 million.
Joey Jacobs, Chairman and Chief Executive Officer of Acadia, commented, “The fourth quarter was a strong finish to a great 2013 for Acadia. We added over 1,000 licensed beds to our operations in 2013, through the completion of seven acquisitions during the year, as well as by adding beds to existing facilities and opening two de novo facilities. As a result, we completed 2013 with approximately 4,200 licensed beds in 51 facilities in 23 states and Puerto Rico compared with more than 3,100 licensed beds in 42 facilities in 21 states at the end of 2012.
“These new beds contributed significantly to our strong revenue growth for the quarter and the year. Our same facility results also reflected the impact of new beds added to the same facility base, as well as our ongoing revenue generation initiatives in each facility. Same facility revenue increased 8.5% for the fourth quarter and 10.0% for fiscal 2013 compared with the same prior-year periods. For the quarter, this increase was driven by a 7.3% rise in patient days and a 1.1% increase in revenue per patient day. Our same-facility revenue growth combined with a continuous focus on operating efficiency enabled us to maintain a fourth quarter same facility EBITDA margin of over 27%. Acadia's adjusted consolidated EBITDA increased 61.1% to $39.2 million, or 20.6% of revenue, for the fourth quarter of 2013 from $24.3 million, or 21.3% of revenue, for the fourth quarter of 2012.
“We recently completed an expansion and extension of our senior secured credit facility. The credit facility is comprised of a $300 million term loan, and the revolving credit facility has been increased to $300 million from $100 million previously. In addition, the interest rate for the entire credit facility, whose maturity was extended to February 2019, is now 50 basis points lower, and we have increased flexibility related to our financial and other restrictive covenants.
“The expanded credit facility positions us well for implementing our growth strategies for 2014. Having already completed one acquisition in January, our current availability under the revolving credit facility is approximately $232 million. Our ratio of total net debt to trailing 12 months adjusted EBITDA was 4.2 at the end of 2013, and we continued to generate significant net cash from continuing operations, with growth of 90.4% to $65.3 million for fiscal 2013.”
Acadia today established its guidance for 2014 earnings per diluted share in a range of $1.26 to $1.29. In addition, Acadia's guidance for earnings per diluted share for the first quarter of 2014 is in a range of $0.27 to $0.28. The Company's guidance does not include the impact of any future acquisitions or transaction-related expenses.
Acadia will hold a conference call to discuss its fourth quarter financial results at 10:00 a.m. Eastern Time on Thursday, February 20, 2014. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available through March 5, 2014.
Risk Factors
This news release contains forward-looking statements. Generally words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this news release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) Acadia's ability to complete acquisitions and successfully integrate the operations of the acquired facilities; (ii) Acadia's ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from the government and third-party payors; (iv) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; and (v) potential operating difficulties, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategy. These factors and others are more fully described in Acadia's periodic reports and other filings with the SEC.
About Acadia
Acadia is a provider of inpatient behavioral healthcare services. Acadia operates a network of 52 behavioral healthcare facilities with more than 4,200 licensed beds in 24 states and Puerto Rico. Acadia provides psychiatric and chemical dependency services to its patients in a variety of settings, including inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and therapeutic school-based programs.
| Acadia Healthcare Company, Inc. | ||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| (in thousands, except per share amounts) | ||||||||||||||||
| Revenue before provision for doubtful accounts | $ | 195,879 | $ | 115,212 | $ | 735,109 | $ | 413,850 | ||||||||
| Provision for doubtful accounts | (5,880 | ) | (960 | ) | (21,701 | ) | (6,389 | ) | ||||||||
| Revenue | 189,999 | 114,252 | 713,408 | 407,461 | ||||||||||||
|
Salaries, wages and benefits (including equity-based compensation expense of $1,505, $576, $5,249 and $2,267, respectively) |
109,058 | 66,049 | 407,962 | 239,639 | ||||||||||||
| Professional fees | 9,877 | 5,498 | 37,171 | 19,019 | ||||||||||||
| Supplies | 9,552 | 5,348 | 37,569 | 19,496 | ||||||||||||
| Rents and leases | 2,672 | 1,594 | 10,049 | 7,838 | ||||||||||||
| Other operating expenses | 21,148 | 12,009 | 80,572 | 42,777 | ||||||||||||
| Depreciation and amortization | 4,842 | 2,650 | 17,090 | 7,982 | ||||||||||||
| Interest expense, net | 9,578 | 7,583 | 37,250 | 29,769 | ||||||||||||
| Debt extinguishment costs | - | - | 9,350 | - | ||||||||||||
| Transaction-related expenses | 3,337 | 6,015 | 7,150 | 8,112 | ||||||||||||
| Total expenses | 170,064 | 106,746 | 644,163 | 374,632 | ||||||||||||
| Income from continuing operations before income taxes | 19,935 | 7,506 | 69,245 | 32,829 | ||||||||||||
| Provision for income taxes | 7,536 | 3,018 | 25,975 | 12,325 | ||||||||||||
| Income from continuing operations | 12,399 | 4,488 | 43,270 | 20,504 | ||||||||||||
| Loss from discontinued operations, net of income taxes | (119 | ) | (123 | ) | (691 | ) | (101 | ) | ||||||||
| Net income | $ | 12,280 | $ | 4,365 | $ | 42,579 | $ | 20,403 | ||||||||
| Basic earnings per share: | ||||||||||||||||
| Income from continuing operations | $ | 0.25 | $ | 0.10 | $ | 0.87 | $ | 0.53 | ||||||||
| Loss from discontinued operations | - | - | (0.02 | ) | - | |||||||||||
| Net income | $ | 0.25 | $ | 0.10 | $ | 0.85 | $ | 0.53 | ||||||||
| Diluted earnings per share: | ||||||||||||||||
| Income from continuing operations | $ | 0.25 | $ | 0.10 | $ | 0.86 | $ | 0.53 | ||||||||
| Loss from discontinued operations | (0.01 | ) | - | (0.01 | ) | - | ||||||||||
| Net income | $ | 0.24 | $ | 0.10 | $ | 0.85 | $ | 0.53 | ||||||||
| Weighted-average shares outstanding: | ||||||||||||||||
| Basic | 50,053 | 43,436 | 50,004 | 38,477 | ||||||||||||
| Diluted | 50,411 | 43,701 | 50,261 | 38,696 | ||||||||||||
| Acadia Healthcare Company, Inc. | |||||||
| Consolidated Balance Sheets | |||||||
| (Unaudited) | |||||||
| December 31, | |||||||
| 2013 | 2012 | ||||||
| (In thousands) | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 4,569 | $ | 49,399 | |||
|
Accounts receivable, net of allowance for doubtful accounts of $18,345 and $7,484, respectively |
95,885 | 63,870 | |||||
| Deferred tax assets | 15,703 | 11,380 | |||||
| Other current assets | 28,969 | 16,332 | |||||
| Total current assets | 145,126 | 140,981 | |||||
| Property and equipment, net | 370,109 | 236,942 | |||||
| Goodwill | 661,549 | 557,402 | |||||
| Intangible assets, net | 20,568 | 15,988 | |||||
| Other assets | 27,307 | 32,100 | |||||
| Total assets | $ | 1,224,659 | $ | 983,413 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Current portion of long-term debt | $ | 15,195 | $ | 7,680 | |||
| Accounts payable | 36,026 | 19,081 | |||||
| Accrued salaries and benefits | 37,721 | 28,749 | |||||
| Other accrued liabilities | 25,748 | 16,341 | |||||
| Total current liabilities | 114,690 | 71,851 | |||||
| Long-term debt | 601,941 | 465,638 | |||||
| Deferred tax liabilities - noncurrent | 7,971 | 998 | |||||
| Other liabilities | 19,347 | 12,376 | |||||
| Total liabilities | 743,949 | 550,863 | |||||
| Equity: | |||||||
| Common stock | 501 | 499 | |||||
| Additional paid-in capital | 461,807 | 456,228 | |||||
| Retained earnings (accumulated deficit) | 18,402 | (24,177 | ) | ||||
| Total equity | 480,710 | 432,550 | |||||
| Total liabilities and equity | $ | 1,224,659 | $ | 983,413 | |||
| Acadia Healthcare Company, Inc. | ||||||||||||
| Consolidated Statements of Cash Flows | ||||||||||||
| (Unaudited) | ||||||||||||
| Year Ended December 31, | ||||||||||||
| 2013 | 2012 | 2011 | ||||||||||
| (In thousands) | ||||||||||||
| Operating activities: | ||||||||||||
| Net income (loss) | $ | 42,579 | $ | 20,403 | $ | (34,892 | ) | |||||
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) continuing operating activities: |
||||||||||||
| Depreciation and amortization | 17,090 | 7,982 | 4,278 | |||||||||
| Amortization of debt issuance costs | 2,264 | 2,507 | 1,271 | |||||||||
| Equity-based compensation expense | 5,249 | 2,267 | 17,320 | |||||||||
| Deferred income tax expense (benefit) | 10,083 | 2,847 | (6,442 | ) | ||||||||
| Loss from discontinued operations, net of taxes | 691 | 101 | 1,698 | |||||||||
| Debt extinguishment costs | 9,350 | - | - | |||||||||
| Other | 21 | (3 | ) | (168 | ) | |||||||
| Change in operating assets and liabilities, net of effect of acquisitions: | ||||||||||||
| Accounts receivable, net | (21,242 | ) | (10,344 | ) | (1,675 | ) | ||||||
| Other current assets | (3,652 | ) | 1,583 | (1,625 | ) | |||||||
| Other assets | (2,239 | ) | 637 | (969 | ) | |||||||
| Accounts payable and other accrued liabilities | (848 | ) | 485 | 3,326 | ||||||||
| Accrued salaries and benefits | 2,803 | 5,142 | (1,759 | ) | ||||||||
| Other liabilities | 3,181 | 702 | 734 | |||||||||
| Net cash provided by (used in) continuing operating activities | 65,330 | 34,309 | (18,903 | ) | ||||||||
| Net cash provided by (used in) discontinued operating activities | 232 | (411 | ) | (1,763 | ) | |||||||
| Net cash provided by (used in) operating activities | 65,562 | 33,898 | (20,666 | ) | ||||||||
| Investing activities: | ||||||||||||
| Cash paid for acquisitions, net of cash acquired | (164,019 | ) | (443,473 | ) | (206,379 | ) | ||||||
| Cash paid for capital expenditures | (68,941 | ) | (27,595 | ) | (9,558 | ) | ||||||
| Cash paid for real estate acquisitions | (8,092 | ) | (53,159 | ) | (8,706 | ) | ||||||
| Other | (1,926 | ) | (417 | ) | (689 | ) | ||||||
| Net cash used in continuing investing activities | (242,978 | ) | (524,644 | ) | (225,332 | ) | ||||||
| Net cash used in discontinued investing activities | - | - | (238 | ) | ||||||||
| Net cash used in investing activities | (242,978 | ) | (524,644 | ) | (225,570 | ) | ||||||
| Financing activities: | ||||||||||||
| Borrowings on long-term debt | 150,000 | 176,063 | 282,485 | |||||||||
| Borrowings on revolving credit facility | 61,500 | 16,000 | 15,100 | |||||||||
| Principal payments on revolving credit facility | (8,000 | ) | (16,000 | ) | (15,100 | ) | ||||||
| Principal payments on long-term debt | (7,680 | ) | (6,000 | ) | (5,063 | ) | ||||||
| Repayment of long-term debt | (52,500 | ) | - | (9,984 | ) | |||||||
| Payment of debt issuance costs | (4,307 | ) | (4,551 | ) | (12,111 | ) | ||||||
| Payment of premium on note redemption | (6,759 | ) | - | - | ||||||||
| Issuances of common stock, net | (205 | ) | 311,841 | 67,162 | ||||||||
| Common stock withheld for minimum statutory taxes, net | (1,242 | ) | 960 | 38 | ||||||||
| Excess tax benefit from equity awards | 1,779 | 714 | - | |||||||||
| Cash distribution paid to equity holders | - | - | (74,441 | ) | ||||||||
| Contribution from Holdings | - | - | 51,029 | |||||||||
| Distributions to equity holders | - | - | (375 | ) | ||||||||
| Net cash provided by financing activities | 132,586 | 479,027 | 298,740 | |||||||||
| Net (decrease) increase in cash and cash equivalents | (44,830 | ) | (11,719 | ) | 52,504 | |||||||
| Cash and cash equivalents at beginning of the period | 49,399 | 61,118 | 8,614 | |||||||||
| Cash and cash equivalents at end of the period | $ | 4,569 | $ | 49,399 | $ | 61,118 | ||||||
| Effect of acquisitions: | ||||||||||||
| Assets acquired, excluding cash | $ | 192,928 | $ | 482,891 | $ | 278,895 | ||||||
| Liabilities assumed | (17,725 | ) | (44,982 | ) | (27,464 | ) | ||||||
| Deposits paid for acquisitions | 500 | 11,684 | - | |||||||||
| Prior year deposits paid for acquisitions | (11,684 | ) | - | - | ||||||||
| Contingent consideration issued in connection with acquisition | - | (6,120 | ) | - | ||||||||
| Issuance of common stock in connection with acquisition | - | - | (44,025 | ) | ||||||||
| Issuance of replacement share-based awards in connection with acquisition | - | - | (1,027 | ) | ||||||||
| Cash paid for acquisitions, net of cash acquired | $ | 164,019 | $ | 443,473 | $ | 206,379 | ||||||
| Acadia Healthcare Company, Inc. | |||||||||||||||||||||||
| Operating Statistics | |||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
| (Revenue in thousands) | |||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| 2013 | 2012 | % Change | 2013 | 2012 | % Change | ||||||||||||||||||
| Same Facility Results (a) | |||||||||||||||||||||||
| Revenue | $ | 121,438 | $ | 111,926 | 8.5 | % | $ | 436,639 | $ | 397,086 | 10.0 | % | |||||||||||
| Patient Days | 196,416 | 183,090 | 7.3 | % | 719,100 | 661,227 | 8.8 | % | |||||||||||||||
| Admissions | 8,421 | 8,276 | 1.7 | % | 31,699 | 29,998 | 5.7 | % | |||||||||||||||
| Average Length of Stay (b) | 23.3 | 22.1 | 5.4 | % | 22.7 | 22.0 | 2.9 | % | |||||||||||||||
| Revenue per Patient Day | $ | 618 | $ | 611 | 1.1 | % | $ | 607 | $ | 601 | 1.1 | % | |||||||||||
| EBITDA margin | 27.1 | % | 27.3 | % | -20 bps | 26.4 | % | 25.0 | % | 140 bps | |||||||||||||
| Total Facility Results | |||||||||||||||||||||||
| Revenue | $ | 189,327 | $ | 113,849 | 66.3 | % | $ | 710,695 | $ | 406,718 | 74.7 | % | |||||||||||
| Patient Days | 284,753 | 188,179 | 51.3 | % | 1,073,136 | 687,794 | 56.0 | % | |||||||||||||||
| Admissions | 15,698 | 8,308 | 89.0 | % | 57,568 | 30,216 | 90.5 | % | |||||||||||||||
| Average Length of Stay (b) | 18.1 | 22.7 | -19.9 | % | 18.6 | 22.8 | -18.1 | % | |||||||||||||||
| Revenue per Patient Day | $ | 665 | $ | 605 | 9.9 | % | $ | 662 | $ | 591 | 12.0 | % | |||||||||||
| EBITDA margin | 24.6 | % | 26.7 | % | -210 bps | 24.3 | % | 24.7 | % | -40 bps | |||||||||||||
|
(a) Same facility results for the comparative three months and year ended December 31, 2013 and 2012 have been adjusted for the impact of a conversion of 50 beds from residential to acute at one of the Company's facilities. The conversion began in the second quarter of 2013 and is expected to be completed in the first quarter of 2014. |
|||||||||||||||||||||||
|
(b) Average length of stay is defined as patient days divided by admissions. |
|||||||||||||||||||||||
| Acadia Healthcare Company, Inc. | |||||||||||||
| Reconciliation of Net Income to Adjusted EBITDA | |||||||||||||
| (Unaudited) | |||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||
| 2013 | 2012 | 2013 | 2012 | ||||||||||
| (in thousands) | (in thousands) | ||||||||||||
| Net income | $ | 12,280 | $ | 4,365 | $ | 42,579 | $ | 20,403 | |||||
| Loss from discontinued operations | 119 | 123 | 691 | 101 | |||||||||
| Provision for income taxes | 7,536 | 3,018 | 25,975 | 12,325 | |||||||||
| Interest expense, net | 9,578 | 7,583 | 37,250 | 29,769 | |||||||||
| Depreciation and amortization | 4,842 | 2,650 | 17,090 | 7,982 | |||||||||
| EBITDA | 34,355 | 17,739 | 123,585 | 70,580 | |||||||||
| Adjustments: | |||||||||||||
| Equity-based compensation expense (a) | 1,505 | 576 | 5,249 | 2,267 | |||||||||
| Debt extinguishment costs (b) | - | - | 9,350 | - | |||||||||
| Transaction-related expenses (c) | 3,337 | 6,015 | 7,150 | 8,112 | |||||||||
| Adjusted EBITDA | $ | 39,197 | $ | 24,330 | $ | 145,334 | $ | 80,959 | |||||
| See footnotes on page 10. | |||||||||||||
| Acadia Healthcare Company, Inc. | |||||||||||||||||
| Reconciliation of Adjusted Income from Continuing Operations to Income from | |||||||||||||||||
| Continuing Operations | |||||||||||||||||
| (Unaudited) | |||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2013 | 2012 | 2013 | 2012 | ||||||||||||||
| (in thousands, except per share amounts) | (in thousands, except per share amounts) | ||||||||||||||||
| Income from continuing operations | $ | 12,399 | $ | 4,488 | $ | 43,270 | $ | 20,504 | |||||||||
| Provision for income taxes | 7,536 | 3,018 | 25,975 | 12,325 | |||||||||||||
| Income from continuing operations before income taxes | 19,935 | 7,506 | 69,245 | 32,829 | |||||||||||||
| Adjustments to income from continuing operations: | |||||||||||||||||
| Debt extinguishment costs (b) | - | - | 9,350 | - | |||||||||||||
| Transaction-related expenses (c) | 3,337 | 6,015 | 7,150 | 8,112 | |||||||||||||
|
Income tax provision/benefit reflecting tax effect of adjustments to income from continuing operations (d) |
(8,797 | ) | (5,435 | ) | (32,172 | ) | (15,353 | ) | |||||||||
| Adjusted income from continuing operations | $ | 14,475 | $ | 8,086 | $ | 53,573 | $ | 25,588 | |||||||||
| Weighted-average shares outstanding - diluted | 50,411 | 43,701 | 50,261 | 38,696 | |||||||||||||
| Adjusted income from continuing operations per diluted share | $ | 0.29 | $ | 0.19 | $ | 1.07 | $ | 0.66 | |||||||||
| See footnotes on page 10. | |||||||||||||||||
| Footnotes |
| We have included certain financial measures in this press release, including EBITDA, Adjusted EBITDA and Adjusted income from continuing operations, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC. We define EBITDA as net income adjusted for loss (income) from discontinued operations, net interest expense, income tax provision and depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for equity-based compensation expense, transaction-related expenses, and debt extinguishment costs. |
| EBITDA, Adjusted EBITDA and Adjusted income from continuing operations are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). EBITDA, Adjusted EBITDA and Adjusted income from continuing operations are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of EBITDA, Adjusted EBITDA and Adjusted income from continuing operations may not be comparable to similarly titled measures of other companies. We have included information concerning EBITDA, Adjusted EBITDA and Adjusted income from continuing operations in this press release because we believe that such information is used by certain investors as measures of a company's historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present EBITDA, Adjusted EBITDA and Adjusted income from continuing operations when reporting their results. Our presentation of EBITDA, Adjusted EBITDA and Adjusted income from continuing operations should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items. |
| (a) Represents the equity-based compensation expense of Acadia. |
| (b) Represents debt extinguishment costs related to the repayment of $52.5 million of the Company's 12.875% Senior Notes due 2018 on March 12, 2013, including a prepayment premium of $6.8 million and the write-off of $2.6 million of deferred financing costs. |
| (c) Represents transaction-related expenses incurred by Acadia related to acquisitions. |
| (d) Represents the income tax provision adjusted to reflect the tax effect of the adjustments to income from continuing operations based on effective tax rates. |
Acadia Healthcare Company, Inc.
Brent Turner, President,
615-861-6000
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
